In preclinical OS models, inhibition of RANKL signalling by a decoy receptor OPG or with a soluble form of its membranous receptor RANK (RANK-Fc) inhibits tumour-associated osteolysis and reduces tumour incidence, local growth, invasion, migration, and lung metastases, leading to increased survival in animals [155–157]. Here, TNFSF11 is linked to neoplasm.